

Abstract of the Disclosure

An aromatic sulfonyl alpha-cycloamino
5 hydroxamic acid compound that *inter alia* inhibits
matrix metalloprotease activity is disclosed as are a
treatment process that comprises administering a
contemplated aromatic sulfonyl alpha-cycloamino
hydroxamic acid compound in a MMP enzyme-inhibiting
10 effective amount to a host having a condition
associated with pathological matrix metalloprotease
activity.